title: Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.
abstract: Evaluation of species differences and systemic exposure multiples (or ratios) in toxicological animal species versus human is an ongoing exercise during the course of drug development. The systemic exposure ratios are best estimated by directly comparing area under the plasma concentration-time curves (AUCs), and sometimes by comparing the dose administered, with the dose being adjusted either by body surface area (BSA) or body weight (BW). In this study, the association between AUC ratio and the administered dose ratio from animals to human were studied using a retrospective data-driven approach. The dataset included nine antisense oligonucleotides (ASOs) with 2'-O-(2-methoxyethyl) modifications, evaluated in two animal species (mouse and monkey) following single and repeated parenteral administrations. We found that plasma AUCs were similar between ASOs within the same species, and are predictable to human exposure using a single animal species, either mouse or monkey. Between monkey and human, the plasma exposure ratio can be predicted directly based on BW-adjusted dose ratios, whereas between mouse and human, the exposure ratio would be nearly fivefold lower in mouse compared to human based on BW-adjusted dose values. Thus, multiplying a factor of 5 for the mouse BW-adjusted dose would likely provide a reasonable AUC exposure estimate in human at steady-state.
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Rosie Z
authors.initials: RZ
authors.lastname: Yu
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: John S
authors.initials: JS
authors.lastname: Grundy
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Scott P
authors.initials: SP
authors.lastname: Henry
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Tae-Won
authors.initials: TW
authors.lastname: Kim
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Norris
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Burkey
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Yanfeng
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Analytical Services, WIL Research Laboratories, Ashland, Ohio, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Vick
authors.affiliation: Preclinical and Clinical Development, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Richard S
authors.initials: RS
authors.lastname: Geary